This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Pyruvate kinase deficiency

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Pyruvate kinase deficiency is a rare cause of inherited haemolytic anaemia especially in Northern European populations. Pyruvate kinase catalyses the last step of glycolysis, which is the conversion of phosphoenolpyruvate to pyruvate, with the formation of one molecule of ATP from ADP.

It has an autosomal recessive mode of inheritance.

Mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency (1):

  • in patients with pyruvate kinase deficiency, mitapivat significantly increased the hemoglobin level, decreased hemolysis, and improved patient-reported outcomes

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.